Comparative Pharmacology
Head-to-head clinical analysis: PROMETHACON versus TAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHACON versus TAVIST.
PROMETHACON vs TAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), antiemetic, sedative, and anticholinergic properties. It inhibits central and peripheral H1 receptors, blocks dopamine D2 receptors in the chemoreceptor trigger zone, and has weak alpha-adrenergic blockade.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
25-50 mg intramuscularly or intravenously every 4-6 hours as needed. Maximum intravenous rate: 25 mg/minute. Maximum daily dose: 150 mg.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 10-14 hours in hepatic impairment
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Renal (80%) as inactive metabolites, 20% fecal via bile
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Category C
Category C
Antihistamine
Antihistamine